Farmacología y Toxicología
Departamento
![Foto de José](/img/nophoto.png)
José
Vivancos Mora
Publicaciones en las que colabora con José Vivancos Mora (22)
2023
-
APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
Frontiers in Neurology, Vol. 14
-
Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial
JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788
2018
-
Farmacología de la enfermedad de Alzheimer y la enfermedad cerebrovascular. Fármacos psicoestimulantes y nootropos
Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 311-324
2014
-
Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARγ and 5-LO-dependent pathways
Journal of Leukocyte Biology, Vol. 95, Núm. 4, pp. 587-598
2013
-
Amelioration of Ischemic brain damage by peritoneal dialysis
Journal of Clinical Investigation, Vol. 123, Núm. 10, pp. 4359-4363
-
N2 neutrophils, novel players in brain inflammation after stroke: Modulation by the pparγ agonist rosiglitazone
Stroke, Vol. 44, Núm. 12, pp. 3498-3508
-
Neuronal excitotoxicity after carotid angioplasty and stent placement procedures
Radiology, Vol. 268, Núm. 2, pp. 515-520
2012
2011
-
Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats
NeuroImage, Vol. 57, Núm. 1, pp. 45-54
2009
-
Synthesis of lipoxin A 4 by 5-lipoxygenase mediates pparγ-dependent, neuroprotective effects of rosiglitazone in experimental stroke
Journal of Neuroscience, Vol. 29, Núm. 12, pp. 3875-3884
2008
-
Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke
Circulation, Vol. 118, Núm. 14, pp. 1450-1459
2007
-
Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke
Stroke, Vol. 38, Núm. 1, pp. 90-95
-
Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection
Journal of Cerebral Blood Flow and Metabolism, Vol. 27, Núm. 7, pp. 1327-1338
-
Statin treatment withdrawal in ischemic stroke: A controlled randomized study
Neurology, Vol. 69, Núm. 9, pp. 904-910
2006
-
A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke
Journal of Experimental Medicine, Vol. 203, Núm. 3, pp. 711-717
-
High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions
Cerebrovascular Diseases, Vol. 22, Núm. 2-3, pp. 123-129
-
Ischemic preconditioning: A novel target for neuroprotective therapy
Cerebrovascular Diseases, Vol. 21, Núm. SUPPL. 2, pp. 38-47
-
Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms
Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229
2005
-
Increased plasma levels of 15-deoxy Δ prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke
Stroke, Vol. 36, Núm. 6, pp. 1189-1194
-
The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke
Journal of Neuropathology and Experimental Neurology, Vol. 64, Núm. 9, pp. 797-805